C4 Therapeutics reprices underwater employee options; new exercise prices $19.00 and $11.88

C4 Therapeutics, Inc.

Eligible options with exercise price >$22.00 repriced to $19.00 for senior leadership and $11.88 for other employees.
Repricing applies to CFO, CBO, CSO, CPO, and CLO; CEO and non-employee directors excluded.
Repriced options revert to original exercise price if holder is terminated for cause or resigns before March 7, 2025.
Board and Committee designed repricing as retention incentive without additional equity grants or cash compensation.
Original exercise price threshold of $22.00 is over 2x the closing price and about 2.5x the 30-day VWAP on effective date.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.